169 related articles for article (PubMed ID: 35898456)
1. Metabolic Characteristics and M2 Macrophage Infiltrates in Invasive Nonfunctioning Pituitary Adenomas.
Lin K; Zhang J; Lin Y; Pei Z; Wang S
Front Endocrinol (Lausanne); 2022; 13():901884. PubMed ID: 35898456
[TBL] [Abstract][Full Text] [Related]
2. A Novel Invasive-Related Biomarker in Three Subtypes of Nonfunctioning Pituitary Adenomas.
Chen Y; Chuan HL; Yu SY; Li CZ; Wu ZB; Li GL; Zhang YZ
World Neurosurg; 2017 Apr; 100():514-521. PubMed ID: 28093347
[TBL] [Abstract][Full Text] [Related]
3. Alterations in CD8
Huang X; Xu J; Wu Y; Sheng L; Li Y; Zha B; Sun T; Yang J; Zang S; Liu J
Pathol Oncol Res; 2021; 27():598887. PubMed ID: 34257554
[TBL] [Abstract][Full Text] [Related]
4. Transcriptome Analysis Identifies an Attenuated Local Immune Response in Invasive Nonfunctioning Pituitary Adenomas.
Kim YH; Kim JH
Endocrinol Metab (Seoul); 2019 Sep; 34(3):314-322. PubMed ID: 31565884
[TBL] [Abstract][Full Text] [Related]
5. Smad3 and phospho-Smad3 are potential markers of invasive nonfunctioning pituitary adenomas.
Liu C; Li Z; Wu D; Li C; Zhang Y
Onco Targets Ther; 2016; 9():2265-71. PubMed ID: 27143922
[TBL] [Abstract][Full Text] [Related]
6. TMT-based quantitative proteomics revealed follicle-stimulating hormone (FSH)-related molecular characterizations for potentially prognostic assessment and personalized treatment of FSH-positive non-functional pituitary adenomas.
Wang Y; Cheng T; Lu M; Mu Y; Li B; Li X; Zhan X
EPMA J; 2019 Dec; 10(4):395-414. PubMed ID: 31832114
[TBL] [Abstract][Full Text] [Related]
7. Nonfunctioning Pituitary Adenoma Recurrence and Its Relationship with Sex, Size, and Hormonal Immunohistochemical Profile.
Batista RL; Trarbach EB; Marques MD; Cescato VA; da Silva GO; Herkenhoff CGB; Cunha-Neto MB; Musolino NR
World Neurosurg; 2018 Dec; 120():e241-e246. PubMed ID: 30138730
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of TGF-β RII expression is correlated with tumor growth and invasion in non-functioning pituitary adenomas.
Gu YH; Feng YG
J Clin Neurosci; 2018 Jan; 47():264-268. PubMed ID: 29031543
[TBL] [Abstract][Full Text] [Related]
9. Identification of a subtype-specific ENC1 gene related to invasiveness in human pituitary null cell adenoma and oncocytomas.
Feng J; Hong L; Wu Y; Li C; Wan H; Li G; Sun Y; Yu S; Chittiboina P; Montgomery B; Zhuang Z; Zhang Y
J Neurooncol; 2014 Sep; 119(2):307-15. PubMed ID: 24916845
[TBL] [Abstract][Full Text] [Related]
10. Untargeted Lipidomics Reveals Specific Lipid Abnormalities in Nonfunctioning Human Pituitary Adenomas.
Hu C; Zhou Y; Feng J; Zhou S; Li C; Zhao S; Shen Y; Hong L; Xuan Q; Liu X; Li Q; Wang X; Zhang Y; Xu G
J Proteome Res; 2020 Jan; 19(1):455-463. PubMed ID: 31601105
[TBL] [Abstract][Full Text] [Related]
11. MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes.
Uraki S; Ariyasu H; Doi A; Takeshima K; Morita S; Inaba H; Furuta H; Fukuhara N; Inoshita N; Nishioka H; Nakao N; Yamada S; Akamizu T
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325698
[TBL] [Abstract][Full Text] [Related]
12. Identification of the proteomic variations of invasive relative to non-invasive non-functional pituitary adenomas.
Zhan X; Desiderio DM; Wang X; Zhan X; Guo T; Li M; Peng F; Chen X; Yang H; Zhang P; Li X; Chen Z
Electrophoresis; 2014 Aug; 35(15):2184-94. PubMed ID: 24729304
[TBL] [Abstract][Full Text] [Related]
13. Fibroblasts play a potential role in bone destruction via osteopontin related caldesmon expression and polymerization in human non-functioning pituitary adenomas.
Zhang LY; Ge XL; Li Z; Tang YJ; Xiong YY; Li XJ; Liu JF; Wanggou SY; Li CT; Yang K; Chen X; Hu ZL; Liu YS; Liu ZX
Sci Rep; 2017 Dec; 7(1):17523. PubMed ID: 29235490
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylated EGFR (pEGFR T693) as a Novel Predictor of Recurrence in Non-Functioning Pituitary Adenomas.
Rai A; Das L; Mukherjee KK; Dhandapani S; Tripathi M; Ahuja CK; Radotra BD; Dutta P
Front Endocrinol (Lausanne); 2021; 12():708111. PubMed ID: 34295309
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Radiographic Characteristics Related to Hyperprolactinemia in Nonfunctioning Pituitary Adenomas.
Park SS; Kim JH; Kim YH; Lee JH; Dho YS; Shin CS
World Neurosurg; 2018 Nov; 119():e1035-e1040. PubMed ID: 30144593
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation profiling in nonfunctioning pituitary adenomas.
Kober P; Boresowicz J; Rusetska N; Maksymowicz M; Goryca K; Kunicki J; Bonicki W; Siedlecki JA; Bujko M
Mol Cell Endocrinol; 2018 Sep; 473():194-204. PubMed ID: 29410024
[TBL] [Abstract][Full Text] [Related]
17. Estrogen Receptor α, a Sex-Dependent Predictor of Aggressiveness in Nonfunctioning Pituitary Adenomas: SSTR and Sex Hormone Receptor Distribution in NFPA.
Øystese KA; Casar-Borota O; Normann KR; Zucknick M; Berg JP; Bollerslev J
J Clin Endocrinol Metab; 2017 Sep; 102(9):3581-3590. PubMed ID: 28911153
[TBL] [Abstract][Full Text] [Related]
18. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Primary Management of Patients With Nonfunctioning Pituitary Adenomas.
Lucas JW; Bodach ME; Tumialan LM; Oyesiku NM; Patil CG; Litvack Z; Aghi MK; Zada G
Neurosurgery; 2016 Oct; 79(4):E533-5. PubMed ID: 27635961
[TBL] [Abstract][Full Text] [Related]
19. Integrative proteomics and transcriptomics identify novel invasive-related biomarkers of non-functioning pituitary adenomas.
Yu SY; Hong LC; Feng J; Wu YT; Zhang YZ
Tumour Biol; 2016 Jul; 37(7):8923-30. PubMed ID: 26753958
[TBL] [Abstract][Full Text] [Related]
20. Integration of quantitative phosphoproteomics and transcriptomics revealed phosphorylation-mediated molecular events as useful tools for a potential patient stratification and personalized treatment of human nonfunctional pituitary adenomas.
Liu D; Li J; Li N; Lu M; Wen S; Zhan X
EPMA J; 2020 Sep; 11(3):419-467. PubMed ID: 32849927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
